These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
172 related items for PubMed ID: 7539119
1. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. Van Etten RA, Debnath J, Zhou H, Casasnovas JM. Oncogene; 1995 May 18; 10(10):1977-88. PubMed ID: 7539119 [Abstract] [Full Text] [Related]
2. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Brasher BB, Roumiantsev S, Van Etten RA. Oncogene; 2001 Nov 22; 20(53):7744-52. PubMed ID: 11753652 [Abstract] [Full Text] [Related]
3. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl. Jackson PK, Paskind M, Baltimore D. Oncogene; 1993 Jul 22; 8(7):1943-56. PubMed ID: 8510937 [Abstract] [Full Text] [Related]
4. Characterization of the proline-rich region of mouse MAPKAP kinase 2: influence on catalytic properties and binding to the c-abl SH3 domain in vitro. Plath K, Engel K, Schwedersky G, Gaestel M. Biochem Biophys Res Commun; 1994 Sep 15; 203(2):1188-94. PubMed ID: 8093038 [Abstract] [Full Text] [Related]
5. An intramolecular SH3-domain interaction regulates c-Abl activity. Barilá D, Superti-Furga G. Nat Genet; 1998 Mar 15; 18(3):280-2. PubMed ID: 9500553 [Abstract] [Full Text] [Related]
6. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain. Mysliwiec T, Perego R, Kruh GD. Oncogene; 1996 Feb 01; 12(3):631-40. PubMed ID: 8637720 [Abstract] [Full Text] [Related]
7. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity. Juang JL, Hoffmann FM. Oncogene; 1999 Sep 16; 18(37):5138-47. PubMed ID: 10498863 [Abstract] [Full Text] [Related]
8. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain. Reichman C, Singh K, Liu Y, Singh S, Li H, Fajardo JE, Fiser A, Birge RB. Oncogene; 2005 Dec 08; 24(55):8187-99. PubMed ID: 16158059 [Abstract] [Full Text] [Related]
9. Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK. Jung JH, Pendergast AM, Zipfel PA, Traugh JA. Biochemistry; 2008 Jan 22; 47(3):1094-104. PubMed ID: 18161990 [Abstract] [Full Text] [Related]
10. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase. Oda T, Kujovich J, Reis M, Newman B, Druker BJ. Oncogene; 1997 Sep 22; 15(11):1255-62. PubMed ID: 9315092 [Abstract] [Full Text] [Related]
11. Coupling of the murine protein tyrosine phosphatase PEST to the epidermal growth factor (EGF) receptor through a Src homology 3 (SH3) domain-mediated association with Grb2. Charest A, Wagner J, Kwan M, Tremblay ML. Oncogene; 1997 Apr 10; 14(14):1643-51. PubMed ID: 9135065 [Abstract] [Full Text] [Related]
12. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. Ren SY, Xue F, Feng J, Skorski T. Exp Hematol; 2005 Oct 10; 33(10):1222-8. PubMed ID: 16219545 [Abstract] [Full Text] [Related]
13. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav. Katzav S. Oncogene; 1993 Jul 10; 8(7):1757-63. PubMed ID: 8510922 [Abstract] [Full Text] [Related]
14. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation. Groysman M, Nagano M, Shaanan B, Katzav S. Oncogene; 1998 Sep 24; 17(12):1597-606. PubMed ID: 9794237 [Abstract] [Full Text] [Related]
15. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding. Fukasawa K, Zhou R, Matten WT, Armstrong AJ, Daar I, Oskarsson M, Sathyanarayana BK, Maclvor L, Wood TG, Vande Woude GF. Oncogene; 1995 Oct 19; 11(8):1447-57. PubMed ID: 7478569 [Abstract] [Full Text] [Related]
16. Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications. Polverini E, Rangaraj G, Libich DS, Boggs JM, Harauz G. Biochemistry; 2008 Jan 08; 47(1):267-82. PubMed ID: 18067320 [Abstract] [Full Text] [Related]
17. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain. Fujita A, Shishido T, Yuan Y, Inamoto E, Narumiya S, Watanabe N. Mol Pharmacol; 2009 Jan 08; 75(1):75-84. PubMed ID: 18835981 [Abstract] [Full Text] [Related]
18. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions. Pisabarro MT, Serrano L, Wilmanns M. J Mol Biol; 1998 Aug 21; 281(3):513-21. PubMed ID: 9698566 [Abstract] [Full Text] [Related]
19. Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src. Shen Z, Batzer A, Koehler JA, Polakis P, Schlessinger J, Lydon NB, Moran MF. Oncogene; 1999 Aug 19; 18(33):4647-53. PubMed ID: 10467411 [Abstract] [Full Text] [Related]
20. Sequence specificity in the recognition of the epidermal growth factor receptor by the abl Src homology 2 domain. Zhu G, Decker SJ, Maclean D, McNamara DJ, Singh J, Sawyer TK, Saltiel AR. Oncogene; 1994 May 19; 9(5):1379-85. PubMed ID: 8152798 [Abstract] [Full Text] [Related] Page: [Next] [New Search]